Clinical Trial

A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-05; most recent amendment 2026-03-18.
Status change: Not Yet Recruiting → Recruiting 2024-11-29
Trial Details
NCT Number NCT06497985
Lead Sponsor Chipscreen Biosciences, Ltd.
Conditions Colorectal Cancer
Enrollment 430 participants
Start Date 2024-12-06
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-19